Daiwa Securities Group Inc. Supernus Pharmaceuticals, Inc. Transaction History
Daiwa Securities Group Inc.
- $27.1 Billion
- Q2 2025
A detailed history of Daiwa Securities Group Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 209 shares of SUPN stock, worth $10,241. This represents 0.0% of its overall portfolio holdings.
Number of Shares
209
Previous 209
-0.0%
Holding current value
$10,241
Previous $7,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SUPN
# of Institutions
315Shares Held
61.7MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$509 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$304 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$236 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$148 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$135 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.62B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...